Amgen pays Nektar $50M for polymer

The cancer drug developer Nektar Therapeutics ($NKTR) has inked a deal to supply a proprietary polymer to Amgen ($AMGN) for $50 million. And in the event it fails to deliver the polymer as contracted, Amgen gains the right of access to the manufacturing facility. Nektar also stands to earn more from the deal if Amgen ups its order. Report

Suggested Articles

Data from a 10,000-patient trial showed that people with osteoarthritis taking Novartis' Ilaris had 40% to 47% lower rates of joint replacements.

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.